Literature DB >> 12795498

The Lifetime Dimensions of Psychosis Scale (LDPS): description and interrater reliability.

Douglas F Levinson1, Bryan J Mowry, Michael A Escamilla, Stephen V Faraone.   

Abstract

A new rating scale, the Lifetime Dimensions of Psychosis Scale (LDPS), is described. The LDPS creates a profile of the lifetime characteristics of each case based on retrospective ratings, encompassing the positive, bizarre, negative, and disorganized symptom factors identified by previous studies of psychotic disorders, plus mood-related symptomatology, degree of deterioration, and complicating factors over the course of illness. A preliminary 39-item scale and instruction manual were developed. Intraclass correlation coefficients (ICCs) for positive symptom and mood item total scores were 0.76 to 0.87 (mean of 0.70 for all items). Highly intercorrelated (tau-b coefficients) or unreliable items were eliminated to create the final 20-item version 2. Good-excellent reliability was observed in a second study using different raters. The LDPS is designed for use by experienced clinicians or researchers who have access to comprehensive clinical information, including semistructured diagnostic interviews, psychiatric records, and family history reports. Dimensional scores and multidimensional patterns might prove useful in studying the relationship of clinical phenotype to genotypes, treatment response, and other variables. They may also be useful in clinical practice.

Entities:  

Mesh:

Year:  2002        PMID: 12795498     DOI: 10.1093/oxfordjournals.schbul.a006972

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  18 in total

1.  Can genomics help usher schizophrenia into the age of RDoC and DSM-6?

Authors:  Ayman H Fanous
Journal:  Schizophr Bull       Date:  2015-05       Impact factor: 9.306

2.  Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample.

Authors:  Brian K Suarez; Jubao Duan; Alan R Sanders; Anthony L Hinrichs; Carol H Jin; Cuiping Hou; Nancy G Buccola; Nancy Hale; Ann N Weilbaecher; Deborah A Nertney; Ann Olincy; Susan Green; Arthur W Schaffer; Christopher J Smith; Dominique E Hannah; John P Rice; Nancy J Cox; Maria Martinez; Bryan J Mowry; Farooq Amin; Jeremy M Silverman; Donald W Black; William F Byerley; Raymond R Crowe; Robert Freedman; C Robert Cloninger; Douglas F Levinson; Pablo V Gejman
Journal:  Am J Hum Genet       Date:  2006-01-03       Impact factor: 11.025

3.  Substance use disorder comorbidity with schizophrenia in families of Mexican and Central American ancestry.

Authors:  Lorena Jiménez-Castro; Elizabeth Hare; Rolando Medina; Henriette Raventos; Humberto Nicolini; Ricardo Mendoza; Alfonso Ontiveros; Alvaro Jerez; Rodrigo Muñoz; Albana Dassori; Michael Escamilla
Journal:  Schizophr Res       Date:  2010-03-19       Impact factor: 4.939

4.  Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence.

Authors:  Emma E M Knowles; Samuel R Mathias; Godfrey D Pearlson; Jennifer Barrett; Josephine Mollon; Dominique Denbow; Katrina Aberzik; Molly Zatony; David C Glahn
Journal:  Schizophr Res       Date:  2018-10-26       Impact factor: 4.939

5.  Cognitive impairment from early to middle adulthood in patients with affective and nonaffective psychotic disorders.

Authors:  Josephine Mollon; Samuel R Mathias; Emma E M Knowles; Amanda Rodrigue; Marinka M G Koenis; Godfrey D Pearlson; Abraham Reichenberg; Jennifer Barrett; Dominique Denbow; Katrina Aberizk; Molly Zatony; Russell A Poldrack; John Blangero; David C Glahn
Journal:  Psychol Med       Date:  2019-01-04       Impact factor: 7.723

6.  Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history.

Authors:  Alan Anticevic; Margaret S Brumbaugh; Anderson M Winkler; Lauren E Lombardo; Jennifer Barrett; Phillip R Corlett; Hedy Kober; June Gruber; Grega Repovs; Michael W Cole; John H Krystal; Godfrey D Pearlson; David C Glahn
Journal:  Biol Psychiatry       Date:  2012-09-11       Impact factor: 13.382

7.  The serotonin transporter 5-HTTPR polymorphism is associated with current and lifetime depression in persons with chronic psychotic disorders.

Authors:  J Contreras; L Hare; B Camarena; D Glahn; A Dassori; R Medina; S Contreras; M Ramirez; R Armas; R Munoz; R Mendoza; H Raventos; A Ontiveros; H Nicolini; R Palmer; M Escamilla
Journal:  Acta Psychiatr Scand       Date:  2008-11-11       Impact factor: 6.392

8.  Reduced white matter integrity in sibling pairs discordant for bipolar disorder.

Authors:  Emma Sprooten; Margaret S Brumbaugh; Emma E M Knowles; D Reese McKay; John Lewis; Jennifer Barrett; Stefanie Landau; Lindsay Cyr; Peter Kochunov; Anderson M Winkler; Godfrey D Pearlson; David C Glahn
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

9.  Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications.

Authors:  Douglas F Levinson; Jubao Duan; Sang Oh; Kai Wang; Alan R Sanders; Jianxin Shi; Nancy Zhang; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Kenneth S Kendler; Robert Freedman; Frank Dudbridge; Itsik Pe'er; Hakon Hakonarson; Sarah E Bergen; Ayman H Fanous; Peter A Holmans; Pablo V Gejman
Journal:  Am J Psychiatry       Date:  2011-02-01       Impact factor: 18.112

10.  Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms.

Authors:  Ayman H Fanous; Baiyu Zhou; Steven H Aggen; Sarah E Bergen; Richard L Amdur; Jubao Duan; Alan R Sanders; Jianxin Shi; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Robert Freedman; Frank Dudbridge; Peter A Holmans; Stephan Ripke; Pablo V Gejman; Kenneth S Kendler; Douglas F Levinson
Journal:  Am J Psychiatry       Date:  2012-12       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.